CompanyAPRENasdaqDoylestown, PA

Aprea Therapeutics

Aprea develops small-molecule inhibitors targeting cancer cell vulnerabilities.

SEC EDGAR ClinicalTrials.gov aprea.com

424B4Sep 22Latest SEC filing

Aug 12Latest story

August 2026

Aprea reports Q2 2026 results, faster enrollment in APR-1051 trial

Aug 12Clinical readoutAPR-1051 Aprea Therapeutics